Listing Performance
▲ 101.63%
Issue Price
₹196
Listing Price
₹395
Listed On
25 Jun 2026
- Price Band
- ₹196 – ₹196
- Lot Size
- 600
- Lot Value
- ₹1,17,600
- Open Date
- 18 Jun 2026
- Close Date
- 22 Jun 2026
- Min Investment
- ₹1,17,600
Avience Biomedicals Limited — Live Stock Performance
IPO Timeline
Issue Opens
18 Jun 2026 · Thu
Issue Closes
22 Jun 2026 · Mon
UPI Deadline
22 Jun 2026 · Mon
Allotment
23 Jun 2026 · Tue
Refund
24 Jun 2026 · Wed
Share Credit
24 Jun 2026 · Wed
Listing
25 Jun 2026 · Thu
About Avience Biomedicals Limited
Avience Biomedicals Limited is an Indian healthcare products company engaged in the manufacturing and supply of diagnostic kits, medical devices and related healthcare products. The company began its operations with diagnostic solutions such as Viral Transport Media (VTM) and test kits for diseases including COVID-19, HIV, HBsAg, malaria and dengue. Over time, it expanded its portfolio to include in-vitro diagnostic (IVD) rapid test kits, serology products, biochemistry analysers and biochemistry reagents. The company serves the healthcare sector by providing products used in disease detection, diagnosis and laboratory testing. Its revenue is primarily generated through the sale of these diagnostic and medical device products. Avience Biomedicals operates in the medical devices and diagnostics segment and focuses on offering healthcare solutions across multiple testing and diagnostic categories.
Investment Analysis
Quick Analysis: 5 strengths · 5 risk factors· Exchange: NSE
Strengths (5)
- •Manufactures a wide range of diagnostic kits, medical devices, analysers and reagents.
- •Serves pathology labs, hospitals, research centres and other healthcare institutions.
- •Holds ISO 9001, ISO 13485, GMP and ZED MSME Gold certifications.
- •Operates a manufacturing facility in Noida with advanced processing capabilities.
- •Has expanded from diagnostic kits to a broader portfolio of healthcare products.
Risk Factors (5)
- •Business performance may be affected by changes in government policies and regulations.
- •Operations depend on the continued services of key management personnel and employees.
- •The company relies on third-party transportation and logistics providers.
- •Market demand and industry fluctuations can impact revenue and profitability.
- •The company has ongoing legal proceedings involving commercial and cheque dishonour matters.
📊 Algorithmic Score
Computed from issue structure — GMP, fresh issue %, OFS %, issue size
Why do these differ? The Algorithmic Score measures issue quality (structure, size, promoter commitment). The Demand Analysis measures investor interest signals (subscription, GMP, risks). A high-quality issue can still have unconfirmed demand — especially before subscription opens.
✍️ Demand & Risk Analysis
Based on market demand signals — subscription, GMP trend, risk factors
IPO Market Analysis
▲ Listed +101.6%Grey market premium is positive at +35%, but subscription data is not yet available so demand cannot be confirmed. A cautious, limited-data view — weigh the company fundamentals before applying.
Pre-listing prediction: NEUTRAL
IPO Details
| Registrar | — |
| Exchange | NSE |
| ISIN | — |
| Face Value | — |
| Issue Size | ₹30.00 Cr |
| Fresh Issue | — |
| OFS Size | — |
| Lead Managers | — |
Company Fundamentals
Capital Structure
Capital structure not yet available.
Shareholding Pattern
Shareholding pattern not yet available.
Reservations & OFS
Reservation & OFS detail not yet available.
Board & Management
Board & management not yet available.
Industry & Market
Industry & market data not yet available.
Application Lot Sizes
Retail caps at ₹2,00,000 (13 lots here). S-HNI is ₹2L–₹10L, B-HNI is above ₹10L.
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 600 | ₹1,17,600 |
| Retail (max) | 13 | 7,800 | ₹15,28,800 |
| S-HNI (min) | 14 | 8,400 | ₹16,46,400 |
| S-HNI (max) | 66 | 39,600 | ₹77,61,600 |
| B-HNI (min) | 67 | 40,200 | ₹78,79,200 |
3-Year Financial Summary
Financial data not available yet.
Subscription Status
| Category | Day 1 | Day 2 | Day 3 |
|---|---|---|---|
| QIB | — | — | — |
| sNII (S-HNI) | — | — | — |
| bNII (B-HNI) | — | — | — |
| Retail | — | — | — |
| Total | — | — | — |
Colour: red <1x · green 1–5x · blue 5–10x · orange >10x.
Allotment Statistics
Allotment probability is estimated based on subscription data and is not guaranteed. Actual allotment depends on the registrar's process.
Basis of Allotment
Category-wise subscription & allotment ratio
Recently Listed IPOs
| Company | Listed | Listing Gain |
|---|---|---|
| Technocrats Plasma Systems | 21 Aug 2026 | +74.24% |
| Skytech Infinite Platform | 21 Aug 2026 | -3.90% |
| ENS Enterprises | 21 Aug 2026 | +4.35% |
Related IPOs
Documents
Frequently Asked Questions
When is the Avience Biomedicals Limited IPO opening?
The Avience Biomedicals Limited IPO opens on 18 Jun 2026 and closes on 22 Jun 2026. Check this page for the latest updates as we refresh every 30 minutes.
What is the price band of the Avience Biomedicals Limited IPO?
The price band for the Avience Biomedicals Limited IPO is ₹196 to ₹196. The final price is announced after the book-building process and is confirmed before listing.
What is the lot size and minimum investment for the Avience Biomedicals Limited IPO?
The minimum lot size is 600 shares with a minimum investment of ₹1,17,600. Retail investors can apply for up to the retail limit defined by SEBI.
What is the GMP of Avience Biomedicals Limited IPO today?
The latest Grey Market Premium for Avience Biomedicals Limited is ₹72 (+34.60%). GMP is unofficial data and is not a guarantee of listing price.
When will the Avience Biomedicals Limited IPO list on NSE and BSE?
The Avience Biomedicals Limited IPO is expected to list on 25 Jun 2026 on NSE. Actual listing day trading begins at the start of the normal market session.
How can I check the Avience Biomedicals Limited IPO allotment status?
You can check your allotment status on the registrar's portal using your PAN, application number, or DP ID. We link to the registrar directly on our allotment page after the allotment date.
Is the Avience Biomedicals Limited IPO a mainboard or SME issue?
Avience Biomedicals Limited is a SME IPO that will list on the NSE Emerge or BSE SME platform. SME IPOs require a minimum application value of one lakh rupees.
How do I apply for the Avience Biomedicals Limited IPO?
You can apply for the Avience Biomedicals Limited IPO through any SEBI-registered broker such as Zerodha, Upstox, or Angel One using UPI or ASBA. Use the Apply Now buttons on this page to go directly to the broker.
What is the expected listing price of Avience Biomedicals Limited IPO?
Based on the current GMP of ₹72, the expected listing price of Avience Biomedicals Limited is ₹268 (issue price ₹196 + GMP ₹72). Note that GMP is unofficial grey market data and actual listing price may differ.
Should I subscribe to Avience Biomedicals Limited IPO?
Based on our algorithmic analysis, Avience Biomedicals Limited IPO is rated NEUTRAL with medium confidence. Grey market premium is positive at +35%, but subscription data is not yet available so demand cannot be confirmed. A cautious, limited-data view — weigh the company fundamentals before applying. This is not investment advice — please read the DRHP and consult a financial advisor before investing.
Related Articles
How to Read Broker and Influencer IPO Recommendations Critically
IPO tips flood social media and broker channels during every busy listing season. Here is how to tell credible analysis from paid hype, what SEBI actually requires, and the red flags worth checking before you trust any recommendation.
Read more →
How-ToHow to Analyse an Upcoming IPO in India: A 10-Step Framework for Retail Investors
A step-by-step guide to analysing an upcoming IPO in India, from reading the DRHP to comparing valuation with peers and treating grey market premium as a secondary signal.
Read more →
How-ToHow to Apply for IPO Online Through UPI in 2026 — Zerodha, Groww, Upstox Guide
Complete guide to applying for an IPO online in India 2026. Step-by-step instructions for Zerodha, Upstox, Angel One, and ASBA net banking.
Read more →